Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2014; 20(23): 7207-7212
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7207
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7207
Table 1 Criteria for stopping nucleos(t)ide analogue therapy in chronic hepatitis B patients
HBeAg-positive chronic hepatitis B | HBeAg-negative chronic hepatitis B | |
APASL 2012 | HBeAg seroconversion with undetectable HBV DNA for at least 12 mo | HBsAg seroclearance or NA therapy > 2 yr and undetectable HBV DNA on three separate occasions, 6 mo apart |
EASL 2012 | HBsAg seroclearance or HBeAg seroconversion with undetectable HBV DNA and 12 mo of consolidation therapy | HBsAg seroclearance |
AASLD 2009 | HBeAg seroconversion with undetectable HBV DNA and > 6 mo of consolidation therapy | HBsAg seroclearance |
Table 2 Off-therapy durability of response to nucleos(t)ide analogue therapy in chronic hepatitis B patients
Ref. | NA | n | Treatment duration | Cumulative relapse rate |
HBeAg-positive CHB | ||||
Song et al[13] | LMV | 98 | 10.3 ± 3.1 mo | 1 yr, 37.5%; 2 yr 49.2% |
Chien et al[14] | LMV | 82 | 16 (3-55) mo | 48%1 |
Dienstag et al[12] | LMV | 39 | 36.6 (4.8-45.6) mo | 77%1 |
Ryu et al[18] | LMV | 61 | 6 mo, 15%; 1 yr, 21%; 2 yr, 31% | |
van Nunen et al[15] | LMV | 59 | 3 yr, 54% | |
Byun et al[16] | LMV | 132 | 14 ± 7 mo | 6 mo, 58%; 1 yr, 66% |
Yoon et al[17] | LMV | 95 | 26 mo | 1 yr, 52%; 2 yr, 55.7% |
Fung et al[44] | LMV | 22 | 23 (5-91) mo | 44%1 |
Lee et al[19] | LMV | 178 | 26 (12-77) mo | 1 yr, 15.9%; 5 yr, 30.2% |
Reijnders et al[21] | Various | 132 | 26 (16-43) mo | 67%1 |
Wang et al[20] | LMV | 82 | 24 (12-54) mo | 1 yr, 23.4%; 2 yr, 25.0%; 4 yr, 29.4% |
Chaung et al[22] | Various | 39 | 90%1 | |
HBeAg-negative CHB | ||||
Santantonio et al[23] | LMV | 15 | 52 wk | 74%1 |
Fung et al[24] | LMV | 50 | 2 yr | 6 mo, 30%; 12 mo, 50%; 18 mo, 50% |
Chien et al[45] | LMV | 85 | 7.4 (6-12) mo | 61%1 |
Chan et al[46] | LMV | 139 | 24 mo | 90%1 |
Shouval et al[47] | ETV | 257 | 48 wk | 3%1 |
LMV | 201 | 48 wk | 5%1 | |
Paik et al[25] | LMV | 50 | 24 mo | 1 yr, 20.9%; 2 yr, 36.0%; 3 yr, 43.1% |
Liu et al[26] | LMV | 61 | ≥ 24 mo | 6 mo, 26.2%; 1 yr, 43.6%; 5 yr, 56.1% |
Hadziyannis et al[27] | ADV | 33 | ≥ 4 yr | 45%1 |
Jeng et al[28] | ETV | 95 | 721 (395-1762) d | 1 yr, 45.3% |
Kim et al[48] | Various | 45 | 6 mo, 48.9%; 1 yr, 73.3% |
- Citation: Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212
- URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7207.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7207